A randomized, double-masked controlled clinical trial of sandostatin long-acting release depot in patients with postsurgical cystoid macular edema

Retina

Volumn 30, Issue 1, 2010, Pages 160-166

  Shah, Syed Mahmood Ali ^a   Nguyen, Quan Dong ^a   Mir, Hafsa Syyida ^b   Polito, Antonio ^a   Hafiz, Gulnar ^a   Tatlipinar, Sinan ^a   Do, Diana V ^a   Vitale, Susan ^a   Haller, Julia A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; OCTREOTIDE; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA LUTEA; SAMPLE SIZE; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, INTRAMUSCULAR; MACULAR EDEMA; MALE; MIDDLE AGED; OCTREOTIDE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RETINA; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 75149163356     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181bced93     Document Type: Article

References (48)

1. Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-931.
2. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004;45:617-624.
3. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-282.
4. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-1433.
5. Fetkenhour CL, Choromokos E, Weinstein J, Shoch D. Cystoid macular edema in retinitis pigmentosa. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977;83:OP515- OP521.
6. Rojas B, Zafirakis P, Christen W, Markomichelakis NN, Foster CS. Medical treatment of macular edema in patients with uveitis. Doc Ophthalmol 1999;97:399-407.
7. Gass JD, Norton EW. Follow-up study of cystoid macular edema following cataract extraction. Trans Am Acad Ophthalmol Otolaryngol 1969;73:665-682.
8. Jampol LM. Cystoid macular edema following cataract surgery. Arch Ophthalmol 1988;106:894-895.
9. Jampol LM. Aphakic cystoid macular edema. A hypothesis. Arch Ophthalmol 1985;103:1134-1135.
10. Levin DS, Lim JI. Update on pseudophakic cystoid macular edema treatment options. Ophthalmol Clin North Am 2002; 15:467-472.
11. Milch FA, Yannuzzi LA. Medical and surgical treatment of aphakic cystoid macular edema. Int Ophthalmol Clin 1987;27: 205-217.
12. Fung WE. Surgical therapy for chronic aphakic cystoid macular edema. Ophthalmology 1982;89:898-901.
13. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology 1998;105:397-405.
14. Abe T, Hayasaka S, Nagaki Y, Kadoi C, Matsumoto M, Hayasaka Y. Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. J Cataract Refract Surg 1999;25:1286-1288.
15. Simo R, Lecube A, Sararols L, et al. Deficit of somatostatinlike immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care 2002;25:2282-2286.
16. Kent D, Vinores SA, Campochiaro PA. Macular oedema: the role of soluble mediators. Br J Ophthalmol 2000;84:542-545.
17. Vinores SA, Amin A, Derevjanik NL, Green WR, Campochiaro PA. Immunohistochemical localization of blood- retinal barrier breakdown sites associated with post-surgical macular oedema. Histochem J 1994;26:655-665.
18. Miyamura N, Mishima K, Honda S, et al. Age and topographic variation of insulin-like growth factor-binding protein 2 in the human RPE. Invest Ophthalmol Vis Sci 2001;42:1626-1630.
19. Martin DM, Yee D, Feldman EL. Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. Brain Res Mol Brain Res 1992;12:181-186.
20. Sall JW, Klisovic DD, O'Dorisio MS, Katz SE. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res 2004;79:465-476.
21. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997;81:228-233.
22. Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C. Regulation of cell proliferation by somatostatin [in French]. Ann Endocrinol (Paris) 2002;63:2S13-2S18.
23. Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE. Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch Clin Exp Ophthalmol 2002;240:227-231.
24. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001;92:545-550. (Pubitemid 32319428)
25. Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:2329-2335.
26. Grant, MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993;48:267-278.
27. Wilson SH, Davis MI, Caballero S, Grant MB. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm IGF Res 2001;11:S53-S59.
28. Yamaguchi K, Gaur VP, Spira AW, Turner JE. Cellular localization of somatostatin mRNA in rat retina. Neuropeptides 1990;17:13-16.
29. Spira AW, Shimizu Y, Rorstad OP. Localization, chromatographic characterization, and development of somatostatin-like immunoreactivity in the guinea pig retina. J Neurosci 1984;4: 3069-3079.
30. Rorstad OP, Senterman MK, Hoyte KM, Martin JB. Immunoreactive and biologically active somatostatin-like material in the human retina. Brain Res 1980;199:488-492.
31. Sagar SM, Rorstad OP, Landis DM, Arnold MA, Martin JB. Somatostatin-like immunoreactive material in the rabbit retina. Brain Res 1982;244:91-99.
32. Rorstad OP, Brownstein MJ, Martin JB. Immunoreactive and biologically active somatostatin-like material in rat retina. Proc Natl Acad Sci USA 1979;76:3019-3023.
33. Sagar SM, Marshall PE. Somatostatin-like immunoreactive material in associational ganglion cells of human retina. Neuroscience 1988;27:507-516.
34. Kuijpers RW, Baarsma S, van Hagen PM. Treatment of cystoid macular edema with octreotide. N Engl J Med 1998;338: 624-626.
35. Yilmaz T, Celebi S, Kukner AS. The protective effects of melatonin, vitamin E and octreotide on retinal edema during ischemia-reperfusion in the guinea pig retina. Eur J Ophthalmol 2002;12:443-449. (Pubitemid 37279120)
36. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-306.
37. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slowrelease octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87: 4554-4563.
38. Rohaizak M, Farndon JR. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. ANZ J Surg 2002;72:635-638.
39. Spaide, RF, Yannuzzi LA, Sisco LJ. Chronic cystoid macular edema and predictors of visual acuity. Ophthalmic Surg 1993; 24:262-267.
40. Degenring RF, Aschmoneit I, Kamppeter B, Budde WM, Jonas JB. Optical coherence tomography and confocal scanning laser tomography for assessment of macular edema. Am J Ophthalmol 2004;138:354-361.
41. Tso, MO. Pathology of cystoid macular edema. Ophthalmology 1982;89:902-915.
42. Hussain MA, Studer K, Messmer EP, Froesch ER. Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. Diabetes 1995;44:1209-1212.
43. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:210-219.
44. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993;36:282-291.
45. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997;12:99-109.
46. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5: 1390-1395.
47. Hernaez-Ortega MC, Soto-Pedre E, Martin JJ. Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience Diabetes Res Clin Pract 2004;64:71-72.
48. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000;23:504-509.